Abbott Laboratories $ABT Stock Holdings Raised by Aviva PLC

Aviva PLC raised its stake in Abbott Laboratories (NYSE:ABT) by 1.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,282,099 shares of the healthcare product maker’s stock after purchasing an additional 36,075 shares during the period. Aviva PLC’s holdings in Abbott Laboratories were worth $285,924,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ABT. Sustainable Insight Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 31.4% in the 4th quarter. Sustainable Insight Capital Management LLC now owns 51,431 shares of the healthcare product maker’s stock valued at $6,444,000 after buying an additional 12,300 shares during the period. RKL Wealth Management LLC boosted its holdings in shares of Abbott Laboratories by 3.6% in the 4th quarter. RKL Wealth Management LLC now owns 3,953 shares of the healthcare product maker’s stock valued at $495,000 after buying an additional 138 shares during the period. Cowa LLC boosted its holdings in shares of Abbott Laboratories by 10.4% in the 4th quarter. Cowa LLC now owns 4,653 shares of the healthcare product maker’s stock valued at $583,000 after buying an additional 438 shares during the period. Nuveen LLC boosted its holdings in shares of Abbott Laboratories by 1.2% in the 4th quarter. Nuveen LLC now owns 11,794,805 shares of the healthcare product maker’s stock valued at $1,477,771,000 after buying an additional 140,244 shares during the period. Finally, Xponance LLC boosted its holdings in shares of Abbott Laboratories by 6.1% in the 4th quarter. Xponance LLC now owns 274,240 shares of the healthcare product maker’s stock valued at $34,360,000 after buying an additional 15,650 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.5%

ABT stock opened at $89.65 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The company has a market capitalization of $156.14 billion, a price-to-earnings ratio of 25.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. The firm’s 50-day moving average is $91.75 and its two-hundred day moving average is $108.12. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the firm earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott helped lead the first close of Star51 Capital’s inaugural medtech venture fund, highlighting its commitment to healthcare innovation and potential future deal flow in medtech. Star51 Capital Announces First Close of Medtech Venture Fund
• Positive Sentiment: Abbott received more support for its diabetes and cancer diagnostics growth story, including CE Mark approval for Libre Duo and updated colorectal cancer screening guidance favoring its tests, which could support long-term revenue growth. Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness
• Positive Sentiment: Abbott’s expanded agreement with MiniMed to commercialize dual glucose-ketone sensors adds another growth avenue in diabetes care and strengthens its connected-device strategy. This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In
• Neutral Sentiment: ABBT was noted as a trending stock on Zacks, suggesting elevated investor attention but not a clear fundamental catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analysts on balance were slightly more cautious, with Erste Group trimming its FY2027 EPS estimate only marginally to $6.04 from $6.05, a small change that does not signal a major shift in outlook. Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT)
• Negative Sentiment: Some investors also pointed to weakness in the stock itself, with recent trading showing ABT underperforming the broader market, suggesting sentiment remains pressured despite the positive product news. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Royal Bank Of Canada decreased their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Benchmark reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Piper Sandler reduced their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Mizuho reduced their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.